scholarly article | Q13442814 |
review article | Q7318358 |
P356 | DOI | 10.1016/S0140-6736(94)90754-4 |
P698 | PubMed publication ID | 7967989 |
P2093 | author name string | K Gelmon | |
P2860 | cites work | Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia | Q34235776 |
Mechanism of action of taxol | Q35255662 | ||
Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines | Q35977537 | ||
Isolation of Chinese hamster ovary cell mutants requiring the continuous presence of taxol for cell division | Q36207411 | ||
Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer | Q40720066 | ||
Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results | Q41085746 | ||
Promotion of microtubule assembly in vitro by taxol | Q41461193 | ||
Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study | Q67520718 | ||
Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms | Q69372459 | ||
Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients | Q72656539 | ||
P433 | issue | 8932 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | docetaxel | Q420436 |
paclitaxel | Q423762 | ||
P304 | page(s) | 1267-1272 | |
P577 | publication date | 1994-11-01 | |
P1433 | published in | The Lancet | Q939416 |
P1476 | title | The taxoids: paclitaxel and docetaxel | |
P478 | volume | 344 |
Q33409451 | A comparative analysis on the efficacy and safety of intaxel® and taxol® in advanced metastatic breast cancer. |
Q74599522 | A review of the pharmacology and clinical activity of new chemotherapeutic agents in lung cancer |
Q92619029 | CREPT is a novel predictor of the response to adjuvant therapy or concurrent chemoradiotherapy in esophageal squamous cell carcinoma |
Q73369103 | Chemotherapy |
Q92029848 | Co-encapsulation of thymoquinone with docetaxel enhances the encapsulation efficiency into PEGylated liposomes and the chemosensitivity of MCF7 breast cancer cells to docetaxel |
Q38934447 | Dermatological adverse events with taxane chemotherapy |
Q44895301 | Disposition kinetics of taxanes after intraperitoneal administration in rats and influence of surfactant vehicles |
Q41495532 | Docetaxel (taxotere, Rhone-Poulenc Rorer). |
Q38938154 | Docetaxel modulates the delayed rectifier potassium current (IK) and ATP-sensitive potassium current (IKATP) in human breast cancer cells. |
Q37683970 | Docetaxel-loaded chitosan microspheres as a lung targeted drug delivery system: in vitro and in vivo evaluation |
Q36461825 | Docetaxel-loaded liposomes: preparation, pH sensitivity, pharmacokinetics, and tissue distribution |
Q41060508 | Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer |
Q34739959 | Effectiveness of cold cap in the prevention of docetaxel-induced alopecia |
Q34366588 | Effects of valproic acid on the cell cycle and apoptosis through acetylation of histone and tubulin in a scirrhous gastric cancer cell line |
Q44533626 | Enhanced effectiveness of last generation antiblastic compounds vs. cisplatin on malignant pleural mesothelioma cell lines |
Q42006799 | Enhanced oral delivery of docetaxel using thiolated chitosan nanoparticles: preparation, in vitro and in vivo studies |
Q40521965 | Evaluation of the effects and adverse drug reactions of low-dose dexamethasone premedication with weekly docetaxel |
Q53289282 | Genome-Wide Association Study on Overall Survival of Advanced Non-small Cell Lung Cancer Patients Treated with Carboplatin and Paclitaxel |
Q44144949 | Growth-inhibiting effects of intralesional docetaxel and paclitaxel on an experimental model of malignant neuroectodermal tumor |
Q37559448 | Impact of Symptom Clusters on Quality of Life Outcomes in Patients from Japan with Advanced Nonsmall Cell Lung Cancers |
Q93896531 | In vitro synergy of paclitaxel (Taxol) and vinorelbine (navelbine) against human melanoma cell lines |
Q44711355 | Influence of neoadjuvant therapy with epirubicin and docetaxel on the expression of HER2/neu in patients with breast cancer. |
Q39312964 | Inhibition of nuclear factor-κB enhances the antitumor effect of paclitaxel against gastric cancer with peritoneal dissemination in mice. |
Q44969545 | Lack of association between amplification of her-2 and response to preoperative taxanes in patients with breast carcinoma |
Q43701818 | Low-dose paclitaxel ameliorates renal fibrosis in rat UUO model by inhibition of TGF-beta/Smad activity |
Q39188081 | Low-dose paclitaxel modulates tumour fibrosis in gastric cancer |
Q90974929 | MicroRNA-421 confers paclitaxel resistance by binding to the KEAP1 3'UTR and predicts poor survival in non-small cell lung cancer |
Q40947187 | N-(4-hydroxyphenyl) retinamide inhibits cystogenesis by polycystic epithelial cell lines in vitro |
Q37473193 | Nanoformulation of natural products for prevention and therapy of prostate cancer |
Q36137260 | Nanoparticulated docetaxel exerts enhanced anticancer efficacy and overcomes existing limitations of traditional drugs |
Q34432179 | Novel molecules that interact with microtubules and have functional activity similar to Taxol |
Q33978189 | Paclitaxel ameliorates fibrosis in hepatic stellate cells via inhibition of TGF-beta/Smad activity |
Q36607944 | Paclitaxel interrupts TGF-beta1 signaling between gallbladder epithelial cells and myofibroblasts |
Q34458673 | Paclitaxel: a pharmacoeconomic review of its use in non-small cell lung cancer |
Q41440111 | Pharmacokinetic optimisation of cancer chemotherapy. Effect on outcomes |
Q35010568 | Phase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumours |
Q55286232 | Phase I study of third-line palliative chemotherapy with low dose paclitaxel for pancreatic cancer. |
Q33686177 | Phase I study of weekly palliative chemotherapy with low-dose third-line paclitaxel for biliary tract cancer |
Q52207123 | Phase I/II trial of high dose mitoxantrone in metastatic breast cancer: the M.D. Anderson Cancer Center experience. |
Q33362114 | Phase II trial of dose-dense paclitaxel, cisplatin, 5-fluorouracil, and leucovorin with filgrastim support in patients with squamous cell carcinoma of the head and neck |
Q26748931 | Predictive value of BRCA1 expression on the efficacy of chemotherapy based on anti-microtubule agents: a pooled analysis across different malignancies and agents |
Q44558863 | Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel |
Q36644465 | Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. |
Q43703440 | Rapid high-performance liquid chromatographic determination of docetaxel (Taxotere) in plasma using liquid-liquid extraction |
Q35052282 | Recent advances in the systemic therapy of breast cancer. |
Q38077764 | Safety and efficacy of cabazitaxel in the docetaxel-treated patients with hormone-refractory prostate cancer. |
Q36424414 | Six minute walking test and carbon monoxide diffusing capacity for non-small cell lung cancer: easy performed tests in every day practice |
Q36424359 | Successful treatment of unresectable gallbladder cancer with low-dose paclitaxel as palliative chemotherapy after failure of gemcitabine and oral S-1: A case report |
Q33916040 | Targeted delivery of albumin bound paclitaxel in the treatment of advanced breast cancer |
Q27023361 | Targeted therapy using nanotechnology: focus on cancer |
Q33800977 | Taxanes: an overview of the pharmacokinetics and pharmacodynamics |
Q34451466 | The role of plant-derived drugs and herbal medicines in healthcare |
Q33642860 | Traditional pharmacology and medicine in Africa. Ethnopharmacological themes in sub-Saharan art objects and utensils |
Q34299276 | Treatment of HIV-associated Kaposi's sarcoma with paclitaxel |
Q73209055 | [Neurologic complications of chemotherapy] |
Q79305388 | [Onycholysis with hyponychium exudate secondary to chemotherapy with paclitaxel and capecitabine] |
Search more.